RMI Partners’s investment focus is novel biopharmaceutical products, medical technologies and diagnostic tools that can help extend human life and make it healthier and more productive. We firmly believe in the future of advanced technology and strive to support innovative projects that are success-oriented and provide adequate profits to the investors.

Our main investment criteria:

      * Novel breakthrough technology

                                                                    * Experienced team

                                                                    * Significant medical problem

                                                                    * Tangible commercial prospects in the market


  • 14 August 2017

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.

  • 10 August 2017

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended  June 30, 2017 . In addition, the Company provided a clinical and business update. As of  June 30, 2017 , Syndax had  $130.0 million  in cash, cash equivalents and short-term investments.